Next 10 |
2024-04-01 09:11:44 ET More on Context Therapeutics Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics Read the full article on Seeking Alpha For...
PHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that on March 28, 2024, the Company submitted an Investigational Ne...
2024-03-21 10:44:50 ET More on Context Therapeutics Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics Read the full article on Seeking Alpha For...
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Context Therape...
2023-11-09 17:45:48 ET More on Context Therapeutics Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics For further details see: Context Therapeutics ...
CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeuti...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Context Therapeutics Inc. (CNTX) is expected to report $-0.3 for Q3 2023
CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models Benchmarking studies comparing CTIM-76 with clinical-stage CLDN6 therapies support CTIM-76's differentiated product profile CTIM-76 IND filing on track for late Q1 2024 Data to be presented...
2023-10-05 12:59:42 ET More on Grupo Aeroportuario del Centro Norte, Grupo Aeroportuario del Pacifico, etc. For further details see: BTWN, OMAB and PAC among mid-day movers
News, Short Squeeze, Breakout and More Instantly...
Context Therapeutics Inc. Company Name:
CNTX Stock Symbol:
NASDAQ Market:
PHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that on March 28, 2024, the Company submitted an Investigational Ne...
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Context Therape...
Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter finan...